Organogenesis Holdings Inc. ORGO
Organogenesis is a leading regenerative medicine company focused on empowering healing through the development, manufacturing, and sale of products for the advanced wound care and surgical and sports medicine markets.
Our mission is advancing healing and recovery beyond expectations. Several of our existing and pipeline products in our portfolio have Premarket Application ("PMA") approval, or 510(k) clearance from the United States Food and Drug Administration ("FDA"). Our solutions address large and growing markets driven by aging demographics and increases in comorbidities such as diabetes, obesity, cardiovascular and peripheral vascular disease. We offer our differentiated products and in-house customer support to a wide range of health care customers including hospitals, wound care centers, government facilities, ambulatory surgery centers ("ASCs") and physician offices.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $564.2M | $482.0M | $433.1M | $450.9M | $467.4M | $338.3M | $261.0M | $193.4M | $198.5M | $138.7M |
| Cost of revenue | — | $115.7M | $106.5M | $105.0M | $114.2M | $87.3M | $75.9M | $68.8M | $61.2M | $48.2M |
| Gross profit | — | $366.3M | $326.7M | $345.9M | $353.2M | $251.0M | $185.0M | $124.6M | $137.3M | $90.5M |
| R&D | $44.5M | $50.3M | $44.4M | $39.8M | $30.7M | $20.1M | $14.8M | $10.7M | $9.1M | $6.3M |
| SG&A | $326.2M | $294.5M | $269.8M | $283.8M | $250.2M | $204.2M | $200.1M | $162.0M | $133.7M | $93.0M |
| Total operating expenses | $519.5M | $483.3M | $420.6M | $323.6M | $280.9M | $224.3M | $214.9M | $176.2M | $142.8M | $99.3M |
| Operating income | $44.7M | -$1.3M | $12.5M | $22.3M | $72.2M | $26.7M | -$29.9M | -$51.6M | -$5.5M | -$8.8M |
| Interest expense | $2.3M | $1.5M | $2.2M | $2.0M | $7.2M | $11.3M | $9.0M | $10.8M | $8.0M | $5.6M |
| Pre-tax income | $47.0M | -$2.8M | $10.4M | $20.3M | $63.1M | $17.8M | -$38.6M | -$64.7M | -$14.6M | -$14.7M |
| Income tax | $9.9M | $3.7M | $5.4M | $4.8M | $31.1M | $530.0K | $150.0K | $84.0K | $7.0M | $65.0K |
| Net income | $37.0M | $900.0K | $4.9M | $15.5M | $94.2M | $17.2M | -$38.7M | -$64.8M | -$8.4M | -$17.0M |
| EPS, basic | 0.16 | -0.01 | 0.04 | 0.12 | 0.73 | 0.16 | -0.42 | -0.94 | — | — |
| EPS, diluted | 0.15 | -0.01 | 0.04 | 0.12 | 0.70 | 0.15 | -0.42 | -0.94 | -0.14 | -0.27 |
| Shares, diluted (wtd. avg.) | $130.2M | $131.7M | $132.7M | $132.4M | $133.7M | $111.4M | $92.8M | $69.3M | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $93.7M | $135.6M | $104.3M | $103.3M | $114.5M | $84.8M | $60.4M | $21.4M | $2.4M | $1.9M |
| Receivables | $217.5M | $109.9M | $82.0M | $89.5M | $82.5M | $56.8M | $39.4M | $34.1M | $28.1M | — |
| Inventory | $29.6M | $26.2M | $28.3M | $24.8M | $25.0M | $27.8M | $22.9M | $13.3M | $14.3M | — |
| Total current assets | $362.2M | $285.9M | $225.0M | $222.6M | $227.0M | $174.3M | $125.6M | $71.1M | $49.7M | $1.4M |
| Property, plant and equipment | $103.7M | $89.1M | $116.2M | $102.5M | $79.2M | $55.8M | $47.2M | $39.6M | $42.1M | — |
| Goodwill | $28.8M | $28.8M | $28.8M | $28.8M | $28.8M | $28.8M | $25.5M | $25.5M | $25.5M | — |
| Other intangibles | $9.1M | $12.5M | $15.9M | $20.8M | $25.7M | $30.6M | $20.8M | $26.1M | $29.8M | — |
| Total assets | $598.7M | $497.9M | $460.0M | $449.4M | $443.3M | $290.2M | $220.7M | $163.7M | $148.7M | $311.4M |
| Accounts payable | $31.9M | $28.9M | $30.7M | $32.3M | $29.3M | $23.4M | $28.4M | $19.2M | $19.1M | — |
| Total current liabilities | $100.1M | $77.5M | $80.5M | $75.0M | $82.7M | $68.2M | $59.9M | $56.1M | $52.0M | $478.4K |
| Long-term debt | — | — | $66.6M | $71.2M | $74.1M | $70.0M | $49.6M | — | $52.1M | — |
| Total liabilities | $164.8M | $112.6M | $181.4M | $183.7M | $201.9M | $148.4M | $165.1M | $116.6M | $157.3M | $11.3M |
| Retained earnings | -$3.1M | -$40.1M | -$41.0M | -$45.3M | -$60.8M | -$155.0M | -$171.0M | -$130.2M | -$65.4M | -$233.9K |
| Total equity | $300.1M | $262.9M | $278.7M | $265.7M | $241.3M | $141.8M | $52.0M | $39.9M | -$15.3M | -$16.0M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$10.3M | $14.2M | $30.9M | $24.9M | $62.0M | $5.5M | -$33.5M | -$60.6M | -$3.5M | -$4.9M |
| Depreciation and amortisation | $15.3M | $13.6M | $10.4M | $5.8M | $5.8M | $4.4M | $3.8M | $3.3M | $3.6M | $5.7M |
| Stock-based compensation | $13.3M | $10.6M | $9.0M | $6.6M | $3.9M | $1.7M | $936.0K | $1.1M | $919.0K | $473.0K |
| Capital expenditure | $14.2M | $10.0M | $24.4M | $33.9M | $31.2M | $17.7M | $6.0M | $1.9M | $2.4M | $1.4M |
| Investing cash flow | -$14.2M | -$10.0M | -$24.4M | -$33.9M | -$31.2M | -$23.5M | -$6.2M | -$1.9M | -$14.9M | -$1.2M |
| Financing cash flow | -$17.4M | $27.6M | -$5.5M | -$2.2M | -$1.0M | $42.5M | $78.7M | $81.5M | $18.9M | $6.8M |
| Buybacks | — | $25.5M | $0 | $0 | — | — | — | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-197357.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |